Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 16/20 | 0.55 |
| ▸ | PPARD | Q03181 | 15/20 | 0.55 |
| ▸ | PPARG | P37231 | 9/20 | 0.55 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5848526 | 0.90 | PPARA (0.47) | PPARAPPARDPPARGFFAR1NPC1 | |
| SCHEMBL5848492 | 0.85 | PPARD (0.62) | PPARAPPARDPPARGFFAR1 | |
| SCHEMBL5848682 | 0.84 | PPARA (0.49) | PPARAPPARDPPARG | |
| SCHEMBL7107434 | 0.83 | PPARD (0.60) | PPARAPPARDPPARGFFAR1 | |
| SCHEMBL5847998 | 0.82 | PPARD (0.48) | PPARAPPARDPPARG | |
| SCHEMBL4823495 | 0.81 | PPARA (0.63) | PPARAPPARDPPARGFFAR1 | |
| SCHEMBL5847993 | 0.76 | PPARD (0.57) | PPARAPPARDPPARGFFAR1 | |
| SCHEMBL4831871 | 0.75 | PPARD (0.53) | PPARAPPARDPPARGFFAR1 | |
| SCHEMBL5848523 | 0.75 | KDM4E (0.43) | PPARAPPARDPPARGNPC1ALDH1A1 | |
| SCHEMBL5849746 | 0.74 | PPARD (0.45) | PPARAPPARDPPARGFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7091225-B2 | Substituted oxazoles and thiazoles as hPPAR alpha agonists | SMITHKLINE BEECHAM CORPORATION (US) | 2006-08-15 | — | — | US | claimed |
| US-20040147571-A1 | Substituted oxazoles and thiazoles as hppar alpha agonists | SMITHKLINE BEECHAM CORPORATION | 2004-07-29 | — | — | US | claimed |
| US-7091225-B2 | Substituted oxazoles and thiazoles as hPPAR alpha agonists | SMITHKLINE BEECHAM CORPORATION (US) | 2006-08-15 | — | — | US | disclosed |
| US-20040147571-A1 | Substituted oxazoles and thiazoles as hppar alpha agonists | SMITHKLINE BEECHAM CORPORATION | 2004-07-29 | — | — | US | disclosed |
| EP-1345916-A1 | SUBSTITUTED OXAZOLES AND THIAZOLES AS HPPAR ALPHA AGONISTS | GLAXO GROUP LIMITED (GB) | 2003-09-24 | — | — | EP | disclosed |
| WO-2002050047-A1 | SUBSTITUED OXAZOLES AND THIAZOLES AS HPPAR ALPHA AGONISTS | GLAXO GROUP LIMITED (GB) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147571-A1 | Substituted oxazoles and thiazoles as hppar alpha agonists | GLP1R, GCGR, CCKAR | PPARA 281/4885PPARD 265/4885PPARG 199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.